Premium
Synergistic Antitumor Effects of Doxorubicin‐Loaded Carboxymethyl Cellulose Nanoparticle in Combination with Endostar for Effective Treatment of Non‐Small‐Cell Lung Cancer
Author(s) -
Li Mingqiang,
Tang Zhaohui,
Lin Jian,
Zhang Yu,
Lv Shixian,
Song Wantong,
Huang Yubin,
Chen Xuesi
Publication year - 2014
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201400108
Subject(s) - doxorubicin , nanomedicine , combination therapy , pharmacology , in vivo , biodistribution , lung cancer , chemotherapy , drug , therapeutic effect , medicine , materials science , cancer research , chemistry , in vitro , nanoparticle , oncology , nanotechnology , biochemistry , biology , microbiology and biotechnology
The multi‐modal combination therapy is proved powerful and successful to enhance the antitumor efficacy in clinics as compared with single therapy modes. In this study, the potential of combining chemotherapy with antiangiogenic therapy for the treatment of non‐small‐cell lung cancer is explored. Towards this aim, OEGylated carboxymethyl cellulose–(2‐(2‐(2‐methoxyethoxy)ethoxy)methyl)oxirane (CMC–ME 2 MO) is prepared by treating CMC with ME 2 MO in the alkaline aqueous solution, and used to efficiently carry doxorubicin (DOX) with high drug‐loading content (16.64%) and encapsulation efficiency (99.78%). As compared to free DOX, the resulting nanoparticles show not only the favorable stability in vitro but also the prolonged blood circulation, improved safety and tolerability, optimized biodistribution, reduced systemic toxicity, and enhanced antitumor efficacy in vivo, indicates a potential utility in cancer chemotherapy. Furthermore, the combination of the DOX‐loaded polysaccharide nanoparticles and antiangiogenic drug endostar provides synergistic effects of chemotherapy and antiangiogenic therapy, which shows the highest efficiency in tumor suppression. The combination approach of the DOX‐containing nanomedicine and endostar for efficient treatment of non‐small‐cell lung cancer is first proposed to demonstrate the synergistic therapeutic effect. This synergistic combination proves to be a promising therapeutic regimen in cancer therapy and holds great potential for clinical application.